Conference Coverage
Conference Coverage
Advances in pancreaticobiliary disease interventions: More options and better outcomes
Evidence-based advances are changing the landscape of pancreaticobiliary disease management.
Conference Coverage
Eosinophilic esophagitis: A year in review
Diet remains the only therapy targeting the cause of EoE and offers a potential drug-free remission.
Conference Coverage
Does private equity ensure survival of GI practices?
Private equity offers the allure of financial and administrative stability.
Conference Coverage
Breakthroughs and challenges in hepatology
“I have witnessed some of the miracles in modern medicine. However, there remain many challenges.’
Conference Coverage
Triple-agonist retatrutide hits new weight loss highs
“I have never seen weight loss at this level” after nearly 1 year of treatment.
Latest News
‘Exciting time for NASH’ with resmetirom phase 3 results
Two doses of resmetirom met the primary endpoints of NASH resolution and no worsening of fibrosis on liver biopsy.
Latest News
ChatGPT in medicine: The good, the bad, and the unknown
Three-expert panel at DDW suggests clinicians should embrace the technology.
Latest News
Etrasimod looks safe for ulcerative colitis out to 2.5 years
If approved by the FDA, etrasimod could become the second agent in the S1P class approved for ulcerative colitis in the United States.
Conference Coverage
Esophageal diseases: Key new concepts
Novel care approaches for esophageal diseases. Highlights from the DDW AGA Postgraduate Course in esophageal conditions.
Conference Coverage
What is new in hepatology in 2023?
There has been a paradigm shift in risk stratification of cirrhosis and targets for prevention and treatment of decompensation.